CV Sciences (CVSI) Profit After Tax (2011 - 2026)
CV Sciences (CVSI) reported Profit After Tax of -$643000.0 for Q1 2026, down 489.91% on a YoY basis from $164910.6 in Q1 2025, and down 212.14% sequentially from -$206000.0 in Q4 2025.
CV Sciences (CVSI) Profit After Tax (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Profit After Tax data on file, last reported at -$643000.0 in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 489.91% year-over-year to -$643000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.5 million (up 20.43% YoY), and the FY2025 full-year result was -$958000.0, up 59.98% from the prior year.
- Profit After Tax eased to -$643000.0 in Q1 2026, from -$206000.0 in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $5.7 million in Q1 2023 to a low of -$2.7 million in Q2 2022.
- A 5-year average of -$481588.2 and a median of -$628000.0 in 2024 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax sank 2477.5% in 2022 and surged 357.37% in 2023, its largest moves.
- Tracing CVSI's Profit After Tax over 5 years: stood at -$1.4 million in 2022, then surged by 37.62% to -$869000.0 in 2023, then increased by 16.46% to -$726000.0 in 2024, then jumped by 71.63% to -$206000.0 in 2025, then tumbled by 212.14% to -$643000.0 in 2026.
- Business Quant data shows CVSI's Profit After Tax at -$643000.0 in Q1 2026, -$206000.0 in Q4 2025, and -$382000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 369.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -643,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -643,000.00 |
| Dec 31, 2025 | -206,000.00 |
| Sep 30, 2025 | -382,000.00 |
| Jun 30, 2025 | -261,000.00 |
| Mar 31, 2025 | -109,000.00 |
| Dec 31, 2024 | -726,000.00 |
| Sep 30, 2024 | -456,000.00 |
| Jun 30, 2024 | -584,000.00 |
| Mar 31, 2024 | -628,000.00 |
| Dec 31, 2023 | -869,000.00 |
| Sep 30, 2023 | -447,000.00 |
| Jun 30, 2023 | -1.29 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Dec 31, 2022 | -1.39 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -2.65 Mn |
| Mar 31, 2022 | -2.22 Mn |
| Dec 31, 2021 | -8.86 Mn |
| Sep 30, 2021 | -40,000.00 |
| Jun 30, 2021 | -3.53 Mn |